ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Utility of Biomarkers to Improve Prediction of Readmission or Mortality After Cardiac Surgery

Friday, November 23, 2018

Submitted by

Claire Vernon

Source

Source Name: The Annals of Thoracic Surgery

Source URL: https://doi.org/10.1016/j.athoracsur.2018.06.052

Author(s)

Jeremiah R. Brown, Jeffrey P. Jacobs, Shama S. Alam, Heather Thiessen-Philbrook, Allen Everett, Donald S. Likosky, Kevin Lobdell, Moritz C. Wyler von Ballmoos, Devin M. Parker, Amit X. Garg, Todd Mackenzie, Marshall L. Jacobs, Chirag R. Parikh

Brown and colleagues evaluated levels of six biomarkers to determine if they improved the prediction of readmission after cardiac surgery: ST2, galectin-3, N-terminal pro-brain natriuretic peptide, cystatin C, interleukin-6, and interleukin-10. The addition of these biomarkers to a model based on only clinical risk factors improved the predictive ability of the model in the derivation cohort (area under the receiver-operating characteristics curve (AUROC) of 0.74 versus 0.66), but it did not improve prediction in an external validation cohort (AUROC of 0.52 versus 0.48).